PrimeRFP SCOUT · Federal Contract Recompete Brief

36C25026N0037Radiopharmaceutical pylarify FSS BPA - BASE — Progenics Pharmaceuticals Inc

Progenics Pharmaceuticals Inc holds $95.0M across 149 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 5 related awards under parent 36C25026A0002. Recompete timing centers on the Sep 30, 2026 PoP end — agencies typically plan 12–18 months ahead.

250-Network Contract Office 10 (36C250)
Awarding office
Progenics Pharmaceuticals Inc
Recipient
Sep 30, 2026
PoP end
$1.1M
Obligated
$1.1M
Potential
325412
NAICS
6505
PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Progenics Pharmaceuticals Inc — $90

Contract facts

Federal
Contract number36C25026N0037
Also listed as36C250-26-N-0037
Also listed as36C25026A0002-36C25026N0037
Agency250-Network Contract Office 10 (36C250)
Awarding office250-Network Contract Office 10 (36C250)
Awarding agencyDepartment of Veterans Affairs (VA)
Funding agencyDepartment of Veterans Affairs (VA)
IncumbentProgenics Pharmaceuticals Inc
CAGE34KE9
UEIYLYKVRPCTCR3
NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505
Parent IDIQ / IDV36C25026A0002
Place of performanceNORTH BILLERICA MA
Pricing typeFirm Fixed Price
Extent competedFull And Open Competition
PoP startOct 1, 2025
PoP end (current)Sep 30, 2026
Obligated$1.1M
Current value$1.1M
Potential value$1.1M

RADIOPHARMACEUTICAL PYLARIFY FSS BPA - BASE YEAR DELIVERY ORDER is a federal award for 250-Network Contract Office 10 (36C250) held by Progenics Pharmaceuticals Inc. Estimated value $1.1M ($1.1M obligated). Current period of performance ends Sep 30, 2026. Place of performance: NORTH BILLERICA MA.

RADIOPHARMACEUTICAL PYLARIFY FSS BPA - BASE YEAR DELIVERY ORDER

Recompete timing

Public
Expiring in 40 days

Current PoP ends Sep 30, 2026 (40 days remaining). Agencies typically plan 12–18 months ahead — at 1.3 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Progenics Pharmaceuticals Inc$95.0M obligated across 149 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).

% of firm-wide obligated ($95.0M) · all agencies
Department of Veterans Affairs (VA)$93.8M · 99%Department of Health and Human Services (HHS)$1.1M · 1%Department of Defense (DOD)$105K · 0%
Open full company profile

Related awards

Same parent · incumbent
36C24625N1142
PYLARIFY F-18 INJECTIONS (336)
$1.2M
Aug 31, 2026
75N90025F00021
PIFLUFOLASTAT F-18 INJECTION DRUGS (PYLARIFY) FROM SOFIE CO.:1108959 [25-004297]
$611K
Sep 25, 2026
36C26126N0023
480 F18 PYLARIFY DOSES POP 1/1/2025 - 12/31/2025
$1.7M
Sep 26, 2026
75N90025F00003
PIFLUFOLASTAT F-18 INJECTION DRUGS (PYLARIFY) FROM SOFIE CO. [POTS 25-000073]
$2.1M
Sep 29, 2026
36C26122N0385
PYLARIFY (PIFLUFOLASTAT F18) NDC: 71258-0022-01
$4.5M
Sep 30, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract 36C25026N0037?

36C25026N0037 (Radiopharmaceutical pylarify FSS BPA - BASE) is a 250-Network Contract Office 10 (36C250) award with a potential value of $1.1M, currently held by Progenics Pharmaceuticals Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C250-26-N-0037?

36C250-26-N-0037 is the dashed form of PIID 36C25026N0037 (Radiopharmaceutical pylarify FSS BPA - BASE), held by Progenics Pharmaceuticals Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C25026N0037?

250-Network Contract Office 10 (36C250) awarded 36C25026N0037 to Progenics Pharmaceuticals Inc (potential $1.1M).

Who is the incumbent on 36C25026N0037?

Progenics Pharmaceuticals Inc is the incumbent with $95.0M across 149 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2026.

When does Progenics Pharmaceuticals Inc’s 36C25026N0037 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 30, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/36C25026N0037